Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrimethamine in Relapsed CLL/SLL
NCT01066663Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2010
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pyrimethamine in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2010; status: completed.
02
Drugs
pyrimethamine
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01066663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01066663.